Adverse events | Group A (N = 49) | AE Grade |
Group B (N = 98) | AE Grade |
P value | ||||
---|---|---|---|---|---|---|---|---|---|
1 | 2 | 3-4 | 1 | 2 | 3-4 | ||||
Fever | 3 | 3 | 0 | 0 | 3 | 9 | 10 | 0 | 0.608‡ |
Nausea | 5 | 3 | 2 | 0 | 5 | 9 | 11 | 0 | 0.852† |
Diarrhea | 3 | 2 | 1 | 0 | 3 | 5 | 5 | 0 | 1‡ |
Pain required treatment | 13 | 10 | 3 | 0 | 13 | 39 | 42 | 0 | 0.007†* |
Liver abscess | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 1‡ |
Puncture hemorrhage | 1 | 1 | 0 | 0 | 1 | 5 | 8 | 0 | 0.274‡ |
Displacement of seeds | 0 | 0 | 0 | 0 | 0 | - | - | - | - |
RILD | 0 | 0 | 0 | 0 | 0 | - | - | - | - |
Tumor response | Intrahepatic Tumor | Tumor in high-risk locations | ||||
---|---|---|---|---|---|---|
Group A (n = 49) | Group B (n = 98) | P value | Group A (n = 49) | Group B (n = 98) | P value | |
Complete response (CR) | 4 | 6 | 5 | 9 | ||
Partial response (PR) | 21 | 23 | 28 | 29 | ||
Stable disease (SD) | 17 | 41 | 13 | 40 | ||
Progressive disease (PD) | 7 | 28 | 3 | 20 | ||
Objective response rate (ORR) (%) | 51.0% | 29.6% | 0.011†* | 67.3% | 38.8% | < 0.001†* |
Disease control rate (DCR) (%) | 85.7% | 71.4% | 0.055† | 93.9% | 79.6% | 0.025†* |
Parameter | Total (N = 181) | Total cohort | PSM cohort | ||||
---|---|---|---|---|---|---|---|
Group A | Group B | P | Group A | Group B | P | ||
N = 49 | N = 132 | value | N = 49 | N = 98 | value | ||
Sex | 0.37 | 0.751 | |||||
Male | 162 (89.5%) | 46 (93.9%) | 116 (87.9%) | 46 (93.9%) | 89 (90.8%) | ||
Female | 19 (10.5%) | 3 (6.12%) | 16 (12.1%) | 3 (6.12%) | 9 (9.18%) | ||
Age (y) | 56.0 [47.0;64.0] | 56.0 [47.0;68.0] | 55.5 [48.0;62.0] | 0.425 | 56.0 [47.0;68.0] | 55.0 [48.0;62.0] | 0.468 |
BCLC | 0.041* | 1 | |||||
B | 72 (39.8%) | 13 (26.5%) | 59 (44.7%) | 13 (26.5%) | 26 (26.5%) | ||
C | 109 (60.2%) | 36 (73.5%) | 73 (55.3%) | 36 (73.5%) | 72 (73.5%) | ||
Maximum median (IQR), tumor mm diameter, | 29.0 [18.0;49.0] | 36.0 [22.0;53.0] | 26.5 [18.0;46.0] | 0.039* | 36.0 [22.0;53.0] | 31.0 [18.0;57.8] | 0.579 |
Tumor number | 0.927 | 0.66 | |||||
1-2 | 60 (33.1%) | 17 (34.7%) | 43 (32.6%) | 17 (34.7%) | 29 (29.6%) | ||
≥ 3 | 121 (66.9%) | 32 (65.3%) | 89 (67.4%) | 32 (65.3%) | 69 (70.4%) | ||
PVTT | 0.202 | 1 | |||||
None | 108 (59.7%) | 25 (51.0%) | 83 (62.9%) | 25 (51.0%) | 49 (50.0%) | ||
Yes | 73 (40.3%) | 24 (49.0%) | 49 (37.1%) | 24 (49.0%) | 49 (50.0%) | ||
Distant metastasis | 0.171 | 0.953 | |||||
None | 109 (60.2%) | 25 (51.0%) | 84 (63.6%) | 25 (51.0%) | 52 (53.1%) | ||
Yes | 72 (39.8%) | 24 (49.0%) | 48 (36.4%) | 24 (49.0%) | 46 (46.9%) | ||
High risk location | 0.045* | 0.76 | |||||
1 | 98 (54.2%) | 33 (67.3%) | 65 (49.2%) | 33 (67.3%) | 62 (63.3%) | ||
2 | 83 (45.8%) | 16 (32.7%) | 67 (50.8%) | 16 (32.7%) | 36 (36.7%) | ||
TACE sessions | 2.00 [1.00;3.00] | 2.00 [1.00;2.00] | 2.00 [1.00;3.00] | 0.442 | 2.00 [1.00;2.00] | 1.00 [1.00;3.00] | 0.464 |
MWA sessions | 1.00 [0.00;2.00] | 1.00 [0.00;2.00] | 1.00 [0.00;2.00] | 0.162 | 1.00 [0.00;2.00] | 1.00 [0.00;2.00] | 0.31 |
Cause of liver disease: | 0.09 | 0.181 | |||||
Continued | |||||||
HCV/HBV | 169 (93.4%) | 43 (87.8%) | 126 (95.5%) | 43 (87.8%) | 93 (94.9%) | ||
Other | 12 (6.6%) | 6 (12.2%) | 6 (4.55%) | 6 (12.2%) | 5 (5.10%) | ||
ECOG score | 0.189 | 0.669 | |||||
0 | 126 (69.6%) | 30 (61.2%) | 96 (72.7%) | 30 (61.2%) | 65 (66.3%) | ||
1 | 55 (30.4%) | 19 (38.8%) | 36 (27.3%) | 19 (38.8%) | 33 (33.7%) | ||
Child-pugh score | 0.563 | 0.386 | |||||
A | 82 (45.3%) | 46 (93.9%) | 36 (27.3%) | 46 (93.9%) | 86 (87.8%) | ||
B | 99 (54.7%) | 3 (6.12%) | 96 (72.7%) | 3 (6.12%) | 12 (12.2%) | ||
AFP, ng/mL | 0.811 | 0.576 | |||||
< 400 | 125 (69.1%) | 35 (71.4%) | 90 (68.2%) | 35 (71.4%) | 64 (65.3%) | ||
≥ 400 | 56 (30.9%) | 14 (28.6%) | 42 (31.8%) | 14 (28.6%) | 34 (34.7%) | ||
PT (s) | 12.2 [11.5;13.1] | 12.0 [11.5;12.8] | 12.3 [11.6;13.1] | 0.167 | 12.0 [11.5;12.8] | 12.2 [11.5;13.1] | 0.331 |
ALB (g/L) | 40.35 [36.2;43.9] | 40.8 [36.7;44.1] | 40.2 [36.0;43.9] | 0.329 | 40.8 [36.7;44.1] | 40.3 [36.1;44.1] | 0.518 |
TBIL (mg/dL) | 13.55 [10.1;19.32] | 12.3 [8.73;18.2] | 14.6 [10.4;20.4] | 0.167 | 12.3 [8.73;18.2] | 14.6 [10.1;20.2] | 0.227 |
Risk Factor | Univariate | Multivariate | ||||
---|---|---|---|---|---|---|
HR | 95%CI | P value | HR | 95%CI | P value | |
Sex | ||||||
Female | 1 | |||||
Male | 0.755 | 0.393–1.451 | 0.399 | |||
Age (y) | ||||||
< 60 | 1 | |||||
≥ 60 | 1.093 | 0.761–1.569 | 0.63 | |||
Maximum diameter (tumor mm) | 1.006 | 1.000–1.013 | 0.071* | 1.003 | 0.996-1.010 | 0.458 |
Tumor number | ||||||
1-2 | 1 | |||||
≥ 3 | 1.104 | 0.915–1.332 | 0.302 | |||
BCLC stage | ||||||
B | 1 | |||||
C | 1.395 | 0.929–2.095 | 0.109 | |||
High-risk location | ||||||
1 | 1 | |||||
2 | 0.665 | 0.456–0.970 | 0.034** | 0.846 | 0.550-1.302 | 0.447 |
PVTT | ||||||
None | ||||||
Yes | 1.615 | 1.124–2.319 | 0.010** | 1.625 | 1.015-2.546 | 0.040** |
Distant metastasis | ||||||
None | ||||||
Yes | 1.099 | 0.772–1.565 | 0.602 | |||
TACE sessions | 1.062 | 0.964–1.170 | 0.223 | |||
MWA sessions | 1.006 | 0.914–1.106 | 0.905 | |||
Treatment | ||||||
TACE+MWA | 1 | |||||
TACE+MWA+ 125I | 0.527 | 0.357–0.778 | 0.002** | 0.479 | 0.328-0.733 | <0.001** |
Cause of liver disease | ||||||
Other | 1 | |||||
HBV/HCV | 1.36 | 0.662–2.791 | 0.402 | |||
ECOG score | ||||||
0 | 1 | |||||
1 | 1.269 | 0.876–1.837 | 0.208 | |||
AFP | ||||||
≤ 400 ng/mL | 1 | |||||
Continued | ||||||
> 400 ng/mL | 1.72 | 1.164–2.542 | 0.006** | 1.403 | 0.948-2.129 | 0.090 |
Prothrombin time (s) | 0.942 | 0.827–1.073 | 0.367 | |||
Albumin (g/L) | 0.987 | 0.951–1.024 | 0.477 | |||
Continued | ||||||
Total Bilirubin (μmol/L) | 1.001 | 0.995–1.008 | 0.649 | |||
Child-pugh class | ||||||
A | 1 | |||||
B | 1.216 | 0.654–2.263 | 0.536 |